Stock, pipeline and biotech catalyst intelligence
Market expectations
Street view at a glance
The average target implies 305.4% upsideTargets are estimates—not guarantees—and can change after company updates.Wall Street consensus
Strong BuyBased on 2 analyst opinionsPrice-target range
$6.00Company profile
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.